| Literature DB >> 25161695 |
Abstract
By introducing the descriptors calculated from the molecular structure, the binding rates of plasma protein (BRPP) with seventy diverse drugs are modeled by a quantitative structure-activity relationship (QSAR) technique. Two algorithms, heuristic algorithm (HA) and support vector machine (SVM), are used to establish linear and nonlinear models to forecast BRPP. Empirical analysis shows that there are good performances for HA and SVM with cross-validation correlation coefficients Rcv(2) of 0.80 and 0.83. Comparing HA with SVM, it was found that SVM has more stability and more robustness to forecast BRPP.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25161695 PMCID: PMC4137739 DOI: 10.1155/2014/957154
Source DB: PubMed Journal: Comput Math Methods Med ISSN: 1748-670X Impact factor: 2.238
Correlation matrix of the six descriptorsa.
| Descriptor | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|
| 1 | 1.000 | 0.177 | 0.776 | 0.039 | −0.190 | −0.559 |
| 2 | 1.000 | 0.266 | 0.269 | −0.104 | −0.255 | |
| 3 | 1.000 | 0.129 | −0.541 | −0.592 | ||
| 4 | 1.000 | −0.192 | −0.497 | |||
| 5 | 1.000 | 0.325 | ||||
| 6 | 1.000 |
a1: ALFA polarizability (DIP), 2: WPSA-3 weighted PPSA (Zefirov's PC), 3: HASA-1/TMSA (Zefirov's PC), 4: Tot point-charge compd. of the molecular dipole, 5: PNSA-2 total charge weighted PNSA, and 6: final heat of formation.
Experimental and calculated BRPP based on HA and SVM.
| No. | Compd. | BRPP/(%) | HA | Residual | SVM | Residual |
|---|---|---|---|---|---|---|
| 1a | Acebutolol | 26.0 | 35.9 | 9.9 | 40.0 | 14.0 |
| 2 | Alprenolol | 85.0 | 61.5 | −23.5 | 72.9 | −12.1 |
| 3 | Amantadine | 67.0 | 58.6 | −8.4 | 61.9 | −5.1 |
| 4 | Amiodarone | 100.0 | 110.9 | 10.9 | 100.3 | 0.3 |
| 5 | Amitriptyline | 94.8 | 100.1 | 5.3 | 90.1 | −4.7 |
| 6a | Aspirin | 49.0 | 56.1 | 7.1 | 45.0 | −4.0 |
| 7 | Betamethasone | 64.0 | 62.9 | −1.1 | 61.0 | −3.0 |
| 8 | Bumetanide | 99.0 | 92.6 | −6.4 | 94.0 | −5.0 |
| 9 | Caffeine | 36.0 | 28.0 | −8.0 | 30.9 | −5.1 |
| 10 | Cefalexin | 14.0 | 41.6 | 27.6 | 41.0 | 27.0 |
| 11a | Chloroquine | 61.0 | 67.7 | 6.7 | 75.6 | 14.6 |
| 12 | Chlorthalidone | 75.0 | 76.8 | 1.8 | 80.0 | 5.0 |
| 13 | Cimetidine | 19.0 | 17.2 | −1.8 | 19.4 | 0.4 |
| 14 | Ciprofloxacin | 40.0 | 40.6 | 0.6 | 43.4 | 3.4 |
| 15 | Diphenhydramine | 78.0 | 83.2 | 5.2 | 83.9 | 5.9 |
| 16a | Furosemide | 98.8 | 85.8 | −13.0 | 95.5 | −3.3 |
| 17 | Glibenclamide | 99.0 | 114.0 | 15.0 | 95.1 | −3.9 |
| 18 | Haloperidol | 92.0 | 91.3 | −0.7 | 95.7 | 3.7 |
| 19 | Lidocaine | 70.0 | 60.6 | −9.4 | 75.1 | 5.1 |
| 20 | Methadone | 89.0 | 94.3 | 5.3 | 94.0 | 5.0 |
| 21a | Methotrexate | 34.0 | 47.3 | 13.3 | 53.4 | 19.4 |
| 22 | Metoclopramide | 40.0 | 37.4 | −2.6 | 44.3 | 4.3 |
| 23 | Metronidazole | 10.0 | 16.1 | 6.1 | 15.0 | 5.0 |
| 24 | Nifedipine | 96.0 | 91.0 | −5.0 | 96.6 | 0.6 |
| 25 | Phenobarbital | 51.0 | 60.4 | 9.4 | 46.2 | −4.8 |
| 26a | Pindoioi | 51.0 | 53.6 | 2.6 | 69.0 | 18.0 |
| 27 | Prednisone | 75.0 | 58.0 | −17.0 | 69.9 | −5.1 |
| 28 | Quinidine | 87.0 | 93.8 | 6.8 | 100.0 | 13.0 |
| 29 | Ranitidine | 15.0 | 15.7 | 0.7 | 15.6 | 0.6 |
| 30 | Sulfadiazine | 54.0 | 65.6 | 11.6 | 59.1 | 5.1 |
| 31a | Sulfamethoxazole | 62.0 | 56.4 | −5.6 | 48.1 | −13.9 |
| 32 | Terbutaline | 20.0 | 39.2 | 19.2 | 25.1 | 5.1 |
| 33 | Timolol | 60.0 | 44.6 | −15.4 | 65.1 | 5.1 |
| 34 | Triamterene | 61.0 | 58.9 | −2.1 | 66.1 | 5.1 |
| 35 | Amikacin | 4.0 | −12.4 | −16.4 | 5.4 | 1.4 |
| 36a | Carbamazepine | 74.0 | 72.2 | −1.8 | 81.8 | 7.8 |
| 37 | Carbenicillin | 50.0 | 63.9 | 13.9 | 55.0 | 5.0 |
| 38 | Cefamandole | 74.0 | 78.7 | 4.7 | 76.1 | 2.1 |
| 39 | Cefazolin | 89.0 | 72.4 | −16.6 | 83.9 | −5.1 |
| 40 | Cefotaxime | 36.0 | 37.1 | 1.1 | 33.6 | −2.4 |
| 41a | Cefuroxime | 33.0 | 52.6 | 19.6 | 53.4 | 20.4 |
| 42 | Chloramphenicol | 53.0 | 37.7 | −15.3 | 47.9 | −5.1 |
| 43 | Chlorothiazide | 94.6 | 83.2 | −11.4 | 89.5 | −5.1 |
| 44 | Clonazepam | 86.0 | 83.1 | −2.9 | 80.9 | −5.1 |
| 45 | Cocaine | 91.0 | 82.2 | −8.8 | 85.9 | −5.1 |
| 46a | Dapsone | 73.0 | 69.0 | −4.0 | 66.6 | −6.4 |
| 47 | Dexamethasone | 68.0 | 78.9 | 10.9 | 73.1 | 5.1 |
| 48 | Diazepam | 98.7 | 88.7 | −10.0 | 93.6 | −5.1 |
| 49 | Ethinylestradiol | 98.0 | 86.2 | −11.8 | 92.9 | −5.1 |
| 50 | Famotidine | 17.0 | 16.2 | −0.8 | 11.9 | −5.1 |
| 51a | Fentanyl | 84.0 | 85.8 | 1.8 | 90.2 | 6.2 |
| 52 | Flecainide | 61.0 | 80.6 | 19.6 | 66.0 | 5.0 |
| 53 | Hydrochlorothiazide | 58.0 | 57.6 | −0.4 | 63.0 | 5.0 |
| 54 | Imipramine | 90.1 | 93.6 | 3.5 | 85.0 | −5.1 |
| 55 | Isoniazid | 0.0 | 17.4 | 17.4 | 5.1 | 5.1 |
| 56a | Isosorbide-5-mononitrate | 0.0 | 10.7 | 10.7 | −11.8 | −11.8 |
| 57 | Ketoconazole | 99.0 | 90.4 | −8.6 | 104.1 | 5.1 |
| 58 | Lovastatin | 95.0 | 101.3 | 6.3 | 100.0 | 5.0 |
| 59 | Mexiletine | 63.0 | 66.3 | 3.3 | 68.1 | 5.1 |
| 60 | Nitrazepam | 87.0 | 97.1 | 10.1 | 94.6 | 7.6 |
| 61a | Norethisterone | 80.0 | 76.1 | −3.9 | 88.3 | 8.3 |
| 62 | Omeprazole | 95.0 | 89.9 | −5.1 | 92.6 | −2.4 |
| 63 | Pethidine | 58.0 | 72.0 | 14.0 | 76.3 | 18.3 |
| 64 | Phenylbutazone | 96.1 | 104.5 | 8.4 | 101.2 | 5.1 |
| 65 | Propafenone | 97.0 | 79.6 | −17.4 | 91.0 | −6.0 |
| 66a | Propranolol | 87.0 | 83.4 | −3.6 | 90.3 | 3.3 |
| 67 | Pyrimethamine | 87.0 | 69.2 | −17.8 | 79.8 | −7.2 |
| 68 | Thiopental | 85.0 | 76.8 | −8.2 | 79.9 | −5.1 |
| 69 | Ticarcillin | 65.0 | 50.7 | −14.3 | 59.9 | −5.1 |
| 70 | Warfarin | 99.0 | 88.0 | −11.0 | 94.0 | −5.0 |
atest set.
Figure 1Forecasted BRPP and observed BRPP based on HA.
Correlation coefficient of six-descriptor in HA model.
| Descriptor | Coefficient |
|
|---|---|---|
| ALFA polarizability (DIP) | 0.653 ± 0.056 | 11.755 |
| aWPSA-3 Weighted PPSA (Zefirov's PC) | −10.969 ± 0.860 | −12.756 |
| aHASA-1/TMSA (Zefirov's PC) | −73.908 ± 14.802 | −4.993 |
| Tot point-charge compd. of the molecular dipole | −7.799 ± 0.918 | −8.495 |
| aPNSA-2 Total charge weighted PNSA | −0.036 ± 0.005 | −7.757 |
| Final heat of formation | −0.059 ± 0.016 | −3.596 |
| R2
= 0.85, |
aTMSA: total molecular surface area; PNSA: partial negative surface area; PPSA: partial positive surface area.
Figure 2Relation of γ and RMS error on LOO cross-validation.
Figure 3Relation of ε and RMS error on LOO cross-validation.
Figure 4Relation of C and RMS error on LOO cross-validation.
Figure 5Forecasted BRPP and observed BRPP of HA.